We are live on ! Find out more
EW icon

Edwards Lifesciences

1,282 hedge funds and large institutions have $46.7B invested in Edwards Lifesciences in 2024 Q1 according to their latest regulatory filings, with 160 funds opening new positions, 437 increasing their positions, 462 reducing their positions, and 106 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more funds holding in top 10

Funds holding in top 10: 9 → 14 (+5)

51% more first-time investments, than exits

New positions opened: 160 | Existing positions closed: 106

19% more capital inflows, than outflows

Capital inflows: $3.8B | Capital outflows: $3.19B

3% more funds holding

Funds holding: 1,246 → 1,282 (+36)

1.74% more ownership

Funds ownership: 79.75% → 81.48% (+1.7%)

10% more call options, than puts

Call options by funds: $431M | Put options by funds: $393M

5% less repeat investments, than reductions

Existing positions increased: 437 | Existing positions reduced: 462

Holders
1,282
Holders Change
+36
Holders Change %
+2.89%
% of All Funds
18.4%
Holding in Top 10
14
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+55.56%
% of All Funds
0.2%
New
160
Increased
437
Reduced
462
Closed
106
Calls
$431M
Puts
$393M
Net Calls
+$38.1M
Net Calls Change
-$64.1M

EW Hedge Fund Activity: Q1 2024 in Review

1,282 of the 6,968 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q1 2024, worth a combined $46.7B — up 26% from $37B a quarter earlier.

Buyers outnumbered sellers: 160 funds opened new EW positions and 106 closed out — a net gain of 54 holders — while 437 added to existing stakes and 462 trimmed.

The largest buyer was Winslow Capital Management, opening a new position worth an estimated $425M. The largest seller was Capital International Investors, cutting an estimated $573M.

  • 1,282 institutional investors held Edwards Lifesciences (EW) as of Q1 2024, up from 1,246 in Q4 2023.
  • Funds reported $46.7B of Edwards Lifesciences stock for Q1 2024, up 26% quarter-over-quarter.
  • 160 funds opened new Edwards Lifesciences positions in Q1 2024 and 106 closed out, a net change of +54 holders.
  • The largest Edwards Lifesciences buyer in Q1 2024 was Winslow Capital Management, an estimated $425M added.
  • The largest Edwards Lifesciences seller in Q1 2024 was Capital International Investors, an estimated $573M sold.

Based on aggregated 13F filings for Q1 2024.